Acadia Pharmaceuticals Inc (ACAD) Institutional Ownership

Ownership Summary

Acadia Pharmaceuticals Inc (NASDAQ:ACAD) currently has 9 active institutional owners and shareholders as of today (December 2025), that have filed 13F forms with the Securities Exchange Commission (SEC).

• The collective stake of institutional investors in Acadia Pharmaceuticals moved to 0.2% in December 2025, a shift down from the 100.2% reported for September 2025.
• On a quarter-over-quarter basis, institutional holdings shifted by -14.75%, with a year-over-year a decrease of 96.93% in the count of filers.
• Of these 9 institutional investors, 3 increased their holdings in Acadia Pharmaceuticals, while 4 of them reduced positions, and 2 investors maintained their exposure.
• This class of investors decreased its holdings in Acadia Pharmaceuticals to 332.45K shares for the 13F-cycle ending December 2025, down by 57.52K shares quarter on quarter, and down 162.76Mn shares year over year.
• With 237.65K shares, NORDEA INVESTMENT MANAGEMENT AB commands the largest institutional position in Acadia Pharmaceuticals as of December 31, 2025, equating to 0.14% of the company.
• Among the most significant buyers of Acadia Pharmaceuticals during December 2025 were SG Americas Securities, LLC (2.29K), Diversified Trust Co (1.94K), GAMMA Investing LLC (48).
• Leading sellers of Acadia Pharmaceuticals stock in December 2025 included NORDEA INVESTMENT MANAGEMENT AB (42.66K), Assenagon Asset Management S.A. (18.90K), Versant Capital Management, Inc (192), True Wealth Design, LLC (43).
• The top 9 institutional holders of Acadia Pharmaceuticals for the quarter ending December 2025 included NORDEA INVESTMENT MANAGEMENT AB (237.65K), SG Americas Securities, LLC (41.97K), Diversified Trust Co (39.82K), Assenagon Asset Management S.A. (8.72K), GAMMA Investing LLC (3.41K), Versant Capital Management, Inc (536), Grove Bank & Trust (200), True Wealth Design, LLC (94), MassMutual Private Wealth & Trust, FSB (62).